Articles in this series • Machlus KR, Aleman MM, Wolberg AS. Update on venous thromboembolism: risk factors, mechanisms, and treatments. Arterioscler Thromb Vasc Biol. 2011;31:476–478. • Popuri RK, Vedantham S. The role of thombolysis in the clinical management of deep vein thrombosis. Arterioscler Thromb Vasc Biol. 2011;31:479–484. • Smalberg JH, Kruip MJHA, Janssen HLA, Rijken DC, Leebeek FWG...

BACKGROUND It is well known that a significant proportion of hospitalized medical and surgical patients with risk factors for deep vein thrombosis (DVT) are not receiving thromboprophylaxis. We designed this study to evaluate the proportion of at-risk patients and the proportion of those receiving recommended prophylaxis. METHODS We conducted a multicentric cross-sectional survey that include...

Background: There are extensive studies indicating that deep venous thrombosis and pulmonary embolism contributes to significant morbidity and mortality after acute ischaemic stroke in the West, with established guidelines for prophylaxis. The situation is less clear in Asia. Accordingly, a literature search was performed to review the available evidence. Methods: A search was performed with al...

For those traveling on long flights, the risk of deep vein thrombosis or pulmonary embolism, generally referred to as venous thromboembolism (VTE), is real and dangerous if left unrecognized or untreated. The goal of this article is to provide an overview of how best to prevent VTE during travel, and how to diagnose and treat it.

THE purpose of this report is to present the experience of a group which has been intensively studying the management of venous thrombosis and pulmonary embolism during the past two years. The importance of this problem is indicated by the fact that the incidence of fatal embolism occurring as a complication of deep venous thrombosis ranges between 3.4 per cent and 5.7 per cent and that 11 to 1...

Recent trials on secondary prophylaxis after venous thromboembolism (VTE) have provided a wealth of data on the risk factors for recurrence and, to some extent, also for bleeding. Some of the results are consistent across the studies, but there are also conflicting data. Certain risk factors, such as pulmonary embolism versus deep vein thrombosis or presence of cardiolipin antibodies, have a mo...

BACKGROUND It has been suggested that statins substantially reduce the risk of venous thromboembolic events. We sought to test this hypothesis by performing a meta-analysis of both published and unpublished results from randomised trials of statins. METHODS AND FINDINGS We searched MEDLINE, EMBASE, and Cochrane CENTRAL up to March 2012 for randomised controlled trials comparing statin with no...

Pulmonary embolism (PE) is a potentially life‐threatening disease with high morbidity and mortality all over the world. PE and deep vein thrombosis (DVT), as two different forms of venous thromboembolism (VTE) on patients, cannot be separated apart in the management. After years of efforts, the management of PE has been comprehensively promoted in China. Medical authorities and staff have gaine...

BACKGROUND Venous thromboembolism (VTE) remains a common problem in critically ill patients. Pharmacologic prophylaxis is currently the standard of care based on high-level evidence from randomized controlled trials. However, limited evidence exists regarding the effectiveness of intermittent pneumatic compression (IPC) devices. The Pneumatic compREssion for preventing VENous Thromboembolism (P...

BACKGROUND Risk assessment models (RAMs) may allow the clinician to determine need for deep vein thrombosis (DVT) prophylaxis. Individual healthcare facilities often develop their own RAMs. The purpose of this study was to determine: 1.) inter-RAM variability in DVT risk factors and contraindications; 2.) inter-rater variability and inter-RAM variability when applying a RAM to a standard case; ...